Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell has reported H119 results in line with expectations. The cash position was £7.6m, with the net loss of £3.24m compensated for by the two equity raises, totalling £14.9m, over the past year. Development appears to be progressing well, with important clinical programmes expected to start patient recruitment during the next two quarters. Additionally, in January 2019 the management team has been strengthened by two important new hires. As detailed in our Initiation note, we value the company, using a risk-adjusted DCF model, at £82.0m, or 21.1p a share.

Market information

Symbol Primary exchange Currency
Last Price Market Cap
52 Week Low 52 Week High


Interim results show progress being maintained
Update | 31 Jan 2019
Missing out on the CRUK Grand Challenge
Lighthouse | 23 Jan 2019
Opening new pathways in immuno-oncology
Initiation | 28 Nov 2018

Recent News

Interim H119 results
31 Jan 2019
Update on CRUK Grand Challenge
23 Jan 2019
Appointment of Head of Research and Head of Manufacturing
21 Jan 2019
Modi 2: extension of Moditope platform
30 Oct 2018